Please assess the completion status of the following clinical trial:

Trial Title: Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with HCC Patients can be included if they require treatment prior to liver transplantation.~* Barcelona Clinic Liver Cancer Stage System class A-B~* One to three tumors of maximum cumulative diameter ≤ 6 cm measured in all 3 axes.~* Measurable disease to be selected as a target on CT/MRI-scan, according to mRECIST criteria for HCC within 6 weeks prior to randomization (≥ 1cm at least in one dimension, suitable for repeated measurement, and arterial enhancement) \[44\].~* Tumor visibility on CT~* Child-Pugh A cirrhosis~* Age ≥ 18 years~* ECOG performance status 0-1~* Albumin\> 28 g/l, bilirubin \< 50 µmol/l, INR \< 2.3, AST/ALT \< 5 times ULN, within 6 weeks prior to randomization~* Platelets will be preferably ≥ 50x10E9/ l (if not, thrombocytes transfusion is allowed to ensure a safe procedure at the discretion of the interventional radiologist and gastroenterologist). Leukocytes \> 1.5x10E9/l, Hb \> 6 mmol/l, within 6 weeks prior to randomization~* Written informed consent~* Willing and able to comply to the follow-up schedule~* Planned to start treatment within 6 weeks from randomization.~Exclusion Criteria:~* Eligibility for resection or RFA~* More than three tumors in the liver~* Ascites~* Any signs of acute viral or non-viral hepatitis~* Encephalopathy~* Vascular tumor invasion (contact with the vessel will not be considered contraindication).~* Previous radiotherapy to the liver~* Known current pregnancy~* Distance from the tumor to the esophagus, stomach, duodenum, small bowel or large bowel \< 0.5 cm on CT or on MRI (randomization imaging). Depending on the SBRT technique used, the minimum acceptable distance may vary and be larger for one technique compared to the other~* Uncontrolled portal hypertension (high bleeding risk). If gastroscopy has been performed, untreated esophageal varices grade III or IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transarterial chemoembolization (Type: ACTIVE_COMPARATOR): Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
- Stereotactic body radiation therapy (Type: EXPERIMENTAL): Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) \< of 5%

Based on this trial design, predict the completion outcome and termination type (if applicable).